Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.312 |
---|---|
High | 0.312 |
Low | 0.312 |
Bid | 0.302 |
Offer | 0.312 |
Previous close | 0.505 |
Average volume | 493.78 |
---|---|
Shares outstanding | 79.99m |
Free float | 79.99m |
P/E (TTM) | -- |
Market cap | 34.40m USD |
EPS (TTM) | -0.7628 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 07:02 GMT.
More ▼
Press releases
- BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.
- BioLineRx to Report Third Quarter 2024 Results on November 25, 2024
- BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024
- BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide
- BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection
More ▼